| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to biotechnology, more specifically to diagnostic and differentiation aids and techniques for various types of breast cancer, and may be used in medicine. The invention is based on measuring the gene expression in a breast cancer sample in the following descriptor groups: (1) ERBB2, STAED3, GRB7, THRAP4, PPARBP; (2) ESR1, GATA3, XBP1, TFF3, ACADSB; (3) KRT5, KRT17, TRIM29, GABRP; (4) KRT18, KRT8, PPP2CA, KRT8L2; (5) PLAU, COL5A2, FAP, THY1; (6) STAT1, UBE2L6, TAP1, LAP3 and (7) SEACAM5, SEACAM6, SEACAM7. The overexpression of most genes in the descriptor group as compared with a normal breast tissue sample indicates that the tissue sample is positive for the given group, whilst the absence of the overexpression of most genes in the descriptor group as compared with the normal breast tissue sample indicates that the tissue sample is negative for the given group. A combination of the positive and/or negative statuses of the descriptive groups forms a set of specific genes for classification of the breast cancer tissue sample.EFFECT: invention provides the clear classification of a breast cancer type for the purpose of clinical assessment of prognosis and toxicity of a drug in a patient suffering breast cancer.12 cl, 22 dwg, 3 tbl |
